A pharmacokinetic model and the clinical pharmacology of cis-platinum, 5-fluorouracil and mitomycin-C in isolated pelvic perfusion

Cancer Chemotherapy and Pharmacology

Volumn 43, Issue 5, 1999, Pages 427-434

  Wanebo, Harold J ^a,b   Belliveau, James F ^c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROGER WILLIAMS MEDICAL CENTER   (United States)

^c PROVIDENCE COLLEGE   (United States)

Author keywords

Clinical pharmacology; Pelvic perfusion; Pharmacokinetics

Indexed keywords

CISPLATIN; FLUOROURACIL; MITOMYCIN C;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG ISOLATION; FEMALE; HEMODIALYSIS; HUMAN; INFANT; INTRAVENOUS DRUG ADMINISTRATION; PELVIS TUMOR; PERFUSION; PRIORITY JOURNAL; TECHNIQUE; TISSUE DISTRIBUTION;

EID: 0033029966     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050918     Document Type: Article

References (19)

1. Collins JM (1989) Pharmacologic rationale for regional drug delivery. J Clin Oncol 2: 498-504
2. Creech O, Krementz ET, Ryan RF, Winblad JN (1958) Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 148: 616-632
3. Darnowski JW, Sawyer RC, Stolfi RL, Martin DS, Lau-Cam CA (1985) Decreased host toxicity in vivo during chronic treatment with 5-fluorouracil. Cancer Chemother Pharmacol 14: 63-69
4. DeConti RC, Toftness BR, Lange RC, Creasey WA (1973) Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). Cancer Res 33: 1310-1315
5. Forastiere A.A, Belliveau JF, Goren M, Vogel WC, Posner MC, O'Leary GP (1988) Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloro-platinum (II) in head and neck cancer patients. Cancer Res 48: 3869-3874
6. Fraile RJ, Baker LH, Buroker TR, Horwitz J, Vaitkevicius VK (1980) Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res 40: 2223-2228
7. Hartigh J den, Oort WJ van (1981) High-pressure liquid chromatographic determination of the antitumor agent mitomycin C in human blood plasma. Anal Chim Acta 127: 47-53
8. Hartigh J den, McVie JG, Oort WJ van, Pinedo HM (1983) Pharmacokinetics of mitomycin C in humans. Cancer Res 43: 5017-5021
9. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB (1987) Clinical phamacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47: 2203-2206
10. LeRoy AF, Lutz RL, Dedrick RL, Litterst CL, Guarino AM (1979) Pharmacokinetic study of cis-dichlorodiammineplatinum(II) (DDP) in the Beagle dog: thermodynamic and kinetic behavior of DDP in a biologic milleu. Cancer Treat Rep 63: 59-71
11. Litterst CL, LeRoy AF, Guarino AM (1979) Disposition and distribution of platinum following parenteral administration of cis-dichlorodiammineplatinum(II) to animals. Cancer Treat Rep 63: 1489-1492
12. Pratt CB, Hayes A, Green AA, Evans WE, Senzer N, Howarth CB, Ransom JL, Crom W (1981) Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors: a phase II study. Cancer Treat Rep 65: 1021-1026
13. Reich SD (1979) Clinical pharmacology of mitomycin C. In: Carter SK, Crooke ST (eds) Mitomycin C: current status and new developments. Academic Press, New York, pp 171-180
14. Turk PS, Belliveau JF, Darnowski JW, Weinberg MC, Leenen L, Wanebo HJ (1993) Isolated pelvic perfusion for unresectable cancer using a balloon occlusion technique. Arch Surg 128: 533-539
15. Vermorken JB, Vijgh WJF van der, Klein I, Hart AAM, Gall HE, Pinedo HM (1984) Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin. Cancer Treat Rep 68: 505-513
16. Wagner JG (1975) In: Fundamentals of Clinical Pharmacokinetics. Drug Intelligence Publications, Bethesda, pp 22-24
17. Wanebo HJ, Chung MD, Levy AI, Turk PS, Vezeridis MP, Belliveau JF (1996) Preoperative therapy for advanced pelvic malignancy by isolated pelvic perfusion with the balloon occlusion technique. Ann Surg Oncol 3: 295-303
18. Wile A, Smolir M (1987) Hyperthermic pelvic isolation-perfusion in the treatment of refractory pelvic cancer. Arch Surg 122: 1321-1325
19. Wile AG, Stemmer EA, Andrews PA, Murphy MP, Abramson IS, Howell SB (1985) Pharmacokinetics of 5-fluorouracil during hyperthermic pelvic isolation-perfusion. J Clin Oncol 3: 849-852